Clinical Trial Update: Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ALLN-177 for reducing urinary oxalate in patients with secondary hyperoxaluria and nephrolithiasis over 28 days; the study has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria
• Nephrolithiasis

Drugs mentioned

• ALLN-177

Snippet

Sponsor: Allena Pharmaceuticals | Conditions: Secondary Hyperoxaluria, Nephrolithiasis | Phase 2 | Status: COMPLETED